MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Audoly, L.
Right arrow Articles by Breyer, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Audoly, L.
Right arrow Articles by Breyer, R. M.

0026-895X/97/010061-08$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 51:61-68 (1997).

Substitution of Charged Amino Acid Residues in Transmembrane Regions 6 and 7 Affect Ligand Binding and Signal Transduction of the Prostaglandin EP3 Receptor

Laurent Audoly and Richard M. Breyer

Division of Nephrology, and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-2372

Expression of the rabbit EP3 receptor isoform 77A in COS1 and HEK293tsA201 cells demonstrated specific binding of [3H]prostaglandin (PG)E2 and receptor-evoked decreases in intracellular cAMP levels. Competition binding with PGE2, PGE2 methyl ester, misoprostol-free acid, misoprostol, and sulprostone suggested that a negative charge at the C1 position is essential for high affinity ligand binding and that the charge at this position is more important than steric bulk. Charged amino acid residues within the transmembrane (TM) domains of the receptor were mutated, and the resulting receptor proteins were analyzed for the effects of these mutations on receptor structure and/or function. Positively charged TM residues are candidates for interaction with the C1 carboxylic acid moiety of prostanoid ligands. Substitution of R329 (TM VII) with either alanine or glutamate resulted in a loss of both detectable [3H]PGE2 binding and receptor activation despite expression of the receptor protein as determined by immunoprecipitation and immunofluorescence. Substitution of K300 (TM VI) with alanine had no effect on binding or signal transduction. Substitution of the conserved aspartic acid at position 338 (TM VII) with alanine caused a loss of detectable receptor-evoked inhibition of cAMP generation, although this mutation did not appreciably affect ligand binding. These studies suggest that R329 but not K300 is a key determinant in receptor/ligand interaction. Furthermore, D338 plays a critical role in Gi activation by the EP3 receptor.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. N. Hata, T. P. Lybrand, and R. M. Breyer
Identification of Determinants of Ligand Binding Affinity and Selectivity in the Prostaglandin D2 Receptor CRTH2
J. Biol. Chem., September 16, 2005; 280(37): 32442 - 32451.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. N. Hata, T. P. Lybrand, L. J. Marnett, and R. M. Breyer
Structural Determinants of Arylacetic Acid Nonsteroidal Anti-Inflammatory Drugs Necessary for Binding and Activation of the Prostaglandin D2 Receptor CRTH2
Mol. Pharmacol., March 1, 2005; 67(3): 640 - 647.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. R. Fortna, A. S. Crystal, V. A. Morais, D. S. Pijak, V. M.-Y. Lee, and R. W. Doms
Membrane Topology and Nicastrin-enhanced Endoproteolysis of APH-1, a Component of the {gamma}-Secretase Complex
J. Biol. Chem., January 30, 2004; 279(5): 3685 - 3693.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
V. L. Schuster, S. Itoh, S. W. Andrews, R. M. Burk, J. Chen, K. M. Kedzie, D. W. Gil, and D. F. Woodward
Synthetic Modification of Prostaglandin F2alpha Indicates Different Structural Determinants for Binding to the Prostaglandin F Receptor Versus the Prostaglandin Transporter
Mol. Pharmacol., April 13, 2001; 58(6): 1511 - 1516.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kotani, I. Tanaka, Y. Ogawa, T. Suganami, T. Matsumoto, S. Muro, Y. Yamamoto, A. Sugawara, Y. Yoshimasa, N. Sagawa, et al.
Multiple Signal Transduction Pathways through Two Prostaglandin E Receptor EP3 Subtype Isoforms Expressed in Human Uterus
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4315 - 4322.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. D. Breyer and R. M. Breyer
Prostaglandin E receptors and the kidney
Am J Physiol Renal Physiol, July 1, 2000; 279(1): F12 - F23.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z.-L. Lu and E. C. Hulme
A Network of Conserved Intramolecular Contacts Defines the Off-state of the Transmembrane Switch Mechanism in a Seven-transmembrane Receptor
J. Biol. Chem., February 25, 2000; 275(8): 5682 - 5686.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
S. Narumiya, Y. Sugimoto, and F. Ushikubi
Prostanoid Receptors: Structures, Properties, and Functions
Physiol Rev, October 1, 1999; 79(4): 1193 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. A. Stillman, M. D. Breyer, and R. M. Breyer
Importance of the Extracellular Domain for Prostaglandin EP2 Receptor Function
Mol. Pharmacol., September 1, 1999; 56(3): 545 - 551.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. L. Pucci, Y. Bao, B. Chan, S. Itoh, R. Lu, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, and V. L. Schuster
Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R734 - R741.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. P. Audoly, L. Ma, I. Feoktistov, S. K. de Foe, M. D. Breyer, and R. M. Breyer
Prostaglandin E-Prostanoid-3 Receptor Activation of Cyclic AMP Response Element-Mediated Gene Transcription
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 140 - 148.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
K. M. Kedzie, J. E. Donello, H. A. Krauss, J. W. Regan, and D. W. Gil
A Single Amino-Acid Substitution in the EP2 Prostaglandin Receptor Confers Responsiveness to Prostacyclin Analogs
Mol. Pharmacol., September 1, 1998; 54(3): 584 - 590.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. Audoly and R. M. Breyer
The Second Extracellular Loop of the Prostaglandin EP3 Receptor Is an Essential Determinant of Ligand Selectivity
J. Biol. Chem., May 23, 1997; 272(21): 13475 - 13478.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z.-L. Lu, J. W. Saldanha, and E. C. Hulme
Transmembrane Domains 4 and 7 of the M1 Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch
J. Biol. Chem., August 31, 2001; 276(36): 34098 - 34104.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics